Medit J Hemat Infect Dis 2009, 1(3), Open Journa MEDITERRANEAN JO Review article Prevention and Treatment Cell Transplant Recipients Suparno Chakrabarti and Somnath Muk Manashi Chakrabarti Foundation For Bl Correspondence to: Dr. Suparno Chakr Road, Kolkata- 700032, West Bengal, IN Published: December 10, 2009 Received: December 3, 2009 Accepted: December 8, 2009 Medit J Hemat Infect Dis 2009, 1(3): e2 This article is available from: http://www This is an Open Access article dis (http://creativecommons.org/licenses/by medium, provided the original work is p Abstract: Infections with Hepa term respectively after HSCT vaccination for HBV-naïve pa post-transplant settings for H recipients result in transmissio enabled effective treatment of might develop so. Selecting a antibody for HBsAg positive pa most challenging aspect of pre therapy and timing of its with this period. Hepatitis C, on th fibrosis and cirrhosis. Early conjectural. The standard com remains sparse, as in the case o grafts result in more consiste donors should be undertaken understanding and recomme infections in HSCT recipients a Introduction: Haematopoietic Transplantation (HSCT) has evolve three decades from a procedure lim haematological malignancies with morbidity and mortality to a muc applicable one across age and donor the explosive expansion of indicat and the new and novel al System OURNAL OF HEMATOLOGY AND INFEC www.mjhid.org ISSN 2035-3006 t of Hepatitis Virus Infections in He s kherjee lood Disorders, Kolkata- 700032, INDIA rabarti, Manashi Chakrabarti Foundation for Blood D NDIA, E-mail: suparno@doctors.org.uk 2009017 DOI 10.4084/MJHID.2009.017 w.mjhid.org/article/view/5184 stributed under the terms of the Creative Comm y/2.0 ), which permits unrestricted use, distribution, properly cited. atitis viruses B and C pose major problems T. The key to prevention for Hepatitis atients and judicial use of anti-viral thera HBV-infected patients. HBsAg positive g on of the virus in about 50%. The newer a post-transplant patients who might be lam a previously infected donor who has hi atients gives the best chance for immunolo eventing HBV reactivation remains the d hdrawal as most reactivations and often fa he other hand affects long-term survival effect of Hepatitis C virus on the imm mbination therapy seems to be effective, b of the use of newer antiviral agents. HSCT ent transmission of the virus and pre-do n to render them non-viremic, if poss endations regarding prevention and ma are discussed. Stem Cell ed over the last mited to high-risk h high risk of ch more widely r barriers. Given tions for HSCT techniques of transplantation, the natu particularly the opportun evolved as well. Hepatitis B are widely prevalent a population, though differen continents. The impact o transplant outcome is gettin recent guideline published jo CTIOUS DISEASES ematopoietic Stem Disorders, 158 PGH Shah mons Attribution License , and reproduction in any s both short and long s B disease remains apy in both pre- and grafts to HBV-naïve anti-viral agents have mivudine-resistant or igh titres of surface ogical clearance. The duration of anti-viral atal ones occur after l with early onset of mune system remains but data on this front T from HCV infected onation treatment of sible. The current anagement of these ure of complications, nistic infections have B and C virus infections amongst the general ntially across the various of these infections on ng better recognised. A ointly by the CIBMTR,